Danaher vs Thermo Fisher: Plasmid Manufacturing & Gene Therapy Positioning
Former VP of Sales, Aldevron
inpractise.com/articles/danaher-vs-thermo-fisher-plasmid-manufacturing-and-gene-therapy-positioning
Danaher vs Thermo Fisher: Plasmid Manufacturing & Gene Therapy Positioning(January 1, 2025)
Former VP of Sales, Aldevron
Interview Transcript
This is a snippet of the transcript, sign up to read more.
How difficult is it for new entrants to come in and manufacture plasmids?
It's amusing how many conversations we have with people who grow a bit of plasmid in a lab and don't understand the complexities involved. They often ask, "Why can't you just make it?" LB broth is inexpensive, so they suggest making a bigger batch. However, it becomes cumbersome when you start using 30-liter fermenters and above. You need a lot of expertise to lyse the cells and maintain DNA integrity, especially with AAV, which is prevalent in the market. The transgene, the main component sourced, is a large plasmid and doesn't behave well at large scales.
This is a snippet of the transcript, sign up to read more.
Related Content
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.